Tanezumab(Tanezumab) - 药物靶点：NGFB_在研适应症：神经痛，神经鞘瘤病_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Tanezumab (genetical recombination) (JAN)、Tanezumab (USAN/INN)、PF-04383119

+ [3]

靶点

NGFB

作用方式

抑制剂

作用机制

NGFB抑制剂(β-神经生长因子抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

Eli Lilly & Co.晖致制药（大连）有限公司Pfizer Europe MA EEIG

权益机构

Eli Lilly & Co.

Pfizer Inc.

Rinat Neuroscience Corp.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)无进展

特殊审评快速通道 (美国)、儿科研究计划 (欧盟)、快速通道 (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 74667H

来源: *****

Sequence Code 107714L

来源: *****

关联

36

项与 Tanezumab 相关的临床试验

NCT04163419

/ Active, not recruiting临床2期IIT

A Phase 2 Randomized, Double-blind, Placebo-Controlled Study of the Analgesic Efficacy and Safety of the Subcutaneous Administration of the Anti-NGF Antibody Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis

The primary objective of this study is to determine whether the administration of tanezumab, an anti-nerve growth factor (NGF) antibody, improves pain relief in schwannomatosis patients receiving background non-NSAID therapy.

开始日期2020-04-30

申办/合作机构

The General Hospital Corp.

[+1]

PER-069-15

/ Recruiting临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER STUDY OF THE LONG- TERM SAFETY AND EFFICACY OF SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

开始日期2016-04-01

申办/合作机构-

NCT02709486

/ Completed临床3期

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE

Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is under clinical investigation for the treatment of pain associated with osteoarthritis or other chronic pain conditions.
The primary objective of this study is to demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24 in subjects with osteoarthritis of the knee or hip. The 2.5 mg dose was shown to provide efficacy benefits with a favorable safety profile when administered intravenously in previous Phase 3 clinical trials. The 5 mg dose is expected to provide added efficacy benefit over the 2.5 mg dose based on data from previous studies.

开始日期2016-03-02

申办/合作机构

Pfizer Inc.

[+1]

100 项与 Tanezumab 相关的临床结果

登录后查看更多信息

100 项与 Tanezumab 相关的转化医学

登录后查看更多信息

100 项与 Tanezumab 相关的专利（医药）

登录后查看更多信息

131

项与 Tanezumab 相关的文献（医药）

2025-09-01·CPT-Pharmacometrics & Systems Pharmacology

Incorporating Multiple Imputation Into Tanezumab Dose–Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo‐Controlled Phase 3 Trials

Article

作者: Marshall, Scott ; Boucher, Martin ; Gaitonde, Puneet

ABSTRACT:

Multiple imputation is increasingly being used to deal with missing data in clinical trials. It is a simulation approach leading to multiple analyses of a pre‐defined number of datasets. For a pre‐defined statistical model, this is relatively straightforward, but for model development as typically conducted in Pharmacometrics, it is unclear how such an approach could be implemented. This case study describes how this was addressed at the time of a regulatory submission and considers alternative approaches which could be adopted in the future.

2024-08-01·VETERINARY JOURNAL

Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

Letter

作者: Reece, Douglas ; Cole, Phaedra ; Simon, Tony ; Werts, Adam

In their letter to the editor, Farrell et al., (2024) presented questions related to canine joint health after treatment with the anti-Nerve Growth Factor (NGF) monoclonal antibody (mAb) bedinvetmab, which was presented as a component of a non-clinical laboratory safety assessment published in Krautmann et al., (2021). Their questions appear to have stemmed from an anti-NGF mAb developed for the treatment of osteoarthritis in humans (tanezumab; FDA, 2021) which in 2021 failed to achieve marketing approval due to an unfavorable benefit: risk profile, primarily due to a syndrome called Rapidly Progressive Osteoarthritis (RPOA) which occurred more commonly in treatment groups when compared to controls. Farrell et. al. (2024) have posed questions on radiographic and histopathologic bone findings from studies included in Krautmann, et al., (2021) and communicated in the FDA's Freedom of Information summary for Librela (FDA, 2023). These findings have previously been determined to be incidental and not bedinvetmab-associated. To address the questions posed, it is important to briefly define RPOA and summarize the syndrome in humans, review why the bone/joint findings in bedinvetmab safety studies in dogs are not indicative of RPOA or an RPOA-like condition, provide an update on joint health after use of bedinvetmab since market approval (>3 years in some markets), and summarize why Zoetis, the manufacturer of Librela, has confidence in joint safety after use of bedinvetmab in dogs.

2023-12-11·The oncologist

A Randomized Placebo-Controlled Trial of the Anti-Nerve Growth Factor Antibody Tanezumab in Subjects With Cancer Pain Due to Bone Metastasis

Article

作者: Fallon, Marie ; Viktrup, Lars ; Bao, Weihang ; Agyemang, Alex ; Brown, Mark T ; Sopata, Maciej ; West, Christine R ; Dragon, Erika

Abstract:

Background:

This phase III, randomized, double-blind, placebo-controlled, parallel-group study assessed the efficacy and safety of tanezumab in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy.

Methods:

Subjects were randomized (stratified by (1) tumor aggressiveness and (2) presence/absence of concomitant anticancer treatment) to placebo or tanezumab 20 mg. Treatment was administered by subcutaneous injection every 8 weeks for 24 weeks (3 doses) followed by a 24-week safety follow-up period. The primary outcome was change in daily average pain in the index bone metastasis cancer pain site (from 0 = no pain to 10 = worst possible pain) from baseline to week 8.

Results:

LS mean (SE) change in pain at week 8 was −1.25 (0.35) for placebo (n = 73) and –2.03 (0.35) for tanezumab 20 mg (n = 72). LS mean (SE) [95% CI] difference from placebo was –0.78 (0.37) [–1.52, –0.04]; P = .0381 with α = 0.0478. The number of subjects with a treatment-emergent adverse event during the treatment period was 50 (68.5%) for placebo and 53 (73.6%) for tanezumab 20 mg. The number of subjects with a prespecified joint safety event was 0 for placebo and 2 (2.8%) for tanezumab 20 mg (pathologic fracture; n = 2).

Conclusion:

Tanezumab 20 mg met the primary efficacy endpoint at week 8. Conclusions on longer-term efficacy are limited since the study was not designed to evaluate the durability of the effect beyond 8 weeks. Safety findings were consistent with adverse events expected in subjects with cancer pain due to bone metastasis and the known safety profile of tanezumab. Clinicaltrials.gov identifier: NCT02609828.

53

项与 Tanezumab 相关的新闻（医药）

2026-02-04

·百度百家

卡梅德生物解读NGF靶点：神经修复与疼痛管理的新希望

在神经科学与生物医药交叉发展的今天，神经生长因子（NGF）作为神经营养因子家族中最早被发现且研究最为深入的成员，正成为神经修复与慢性疼痛干预的关键靶点。其独特的生物学功能和明确的作用机制，为抗体药物研发开辟了全新赛道。 NGF主要通过与两类受体结合发挥作用：高亲和力的TrkA受体和低亲和力的p75受体。当NGF与TrkA结合后，可激活下游信号通路，促进神经元存活、轴突生长及突触可塑性；而与p75受体相互作用时，则在特定条件下调控细胞凋亡，维持神经系统的动态平衡。此外，NGF还参与免疫调节与组织修复过程，展现出多维度的生理调控能力。基于这一机制，靶向NGF的抗体药物近年来取得显著进展。以Tanezumab为代表的人源化单克隆抗体，能够特异性中和游离NGF，阻断其与受体结合，从而有效抑制异常痛觉信号传导。该类药物因分子量大，难以穿透血脑屏障，显著降低了中枢神经系统相关不良反应风险，在骨关节炎、慢性下腰痛及糖尿病周围神经病变等疼痛适应症中展现出良好疗效与安全性。目前，Fulranumab等新一代抗NGF抗体也已进入临床研究阶段，进一步丰富治疗选择。除抗体药物外，国内已有多种外源性NGF制剂用于临床，如用于视神经损伤或周围神经炎的修复治疗，通过补充功能性NGF蛋白，支持受损神经的再生与功能恢复。尽管这类产品多为非抗体形式，但其应用验证了NGF在神经修复中的核心价值。展望未来，NGF靶点的研发正朝着更高精度与更广适应症方向演进。一方面，通过抗体工程优化亲和力、延长半衰期并规避罕见副作用（如快速进展性骨关节病），提升药物安全性；另一方面，双特异性抗体设计有望实现NGF与其他疼痛或神经退行相关通路的协同调控。此外，NGF在眼科疾病（如青光眼）、神经退行性病变及自身免疫相关神经损伤中的潜在应用，也为新药开发提供广阔空间。值得关注的是，NGF与干细胞技术的融合——利用其引导干细胞定向分化为功能性神经元——可能为重度神经损伤带来再生医学新策略。卡梅德生物可以提供NGF靶点相关的重组蛋白表达、单克隆抗体开发、受体-配体相互作用分析及体外神经元模型构建等技术服务，助力科研机构与药企加速神经修复与疼痛管理领域的创新药物研发。

2026-02-04

·有驾

卡梅德生物解读NGF靶点：神经修复与疼痛管理的新希望

在神经科学与生物医药交叉发展的今天，神经生长因子（NGF）作为神经营养因子家族中最早被发现且研究最为深入的成员，正成为神经修复与慢性疼痛干预的关键靶点。其独特的生物学功能和明确的作用机制，为抗体药物研发开辟了全新赛道。 NGF主要通过与两类受体结合发挥作用：高亲和力的TrkA受体和低亲和力的p75受体。当NGF与TrkA结合后，可激活下游信号通路，促进神经元存活、轴突生长及突触可塑性；而与p75受体相互作用时，则在特定条件下调控细胞凋亡，维持神经系统的动态平衡。此外，NGF还参与免疫调节与组织修复过程，展现出多维度的生理调控能力。基于这一机制，靶向NGF的抗体药物近年来取得显著进展。以Tanezumab为代表的人源化单克隆抗体，能够特异性中和游离NGF，阻断其与受体结合，从而有效抑制异常痛觉信号传导。该类药物因分子量大，难以穿透血脑屏障，显著降低了中枢神经系统相关不良反应风险，在骨关节炎、慢性下腰痛及糖尿病周围神经病变等疼痛适应症中展现出良好疗效与安全性。目前，Fulranumab等新一代抗NGF抗体也已进入临床研究阶段，进一步丰富治疗选择。除抗体药物外，国内已有多种外源性NGF制剂用于临床，如用于视神经损伤或周围神经炎的修复治疗，通过补充功能性NGF蛋白，支持受损神经的再生与功能恢复。尽管这类产品多为非抗体形式，但其应用验证了NGF在神经修复中的核心价值。展望未来，NGF靶点的研发正朝着更高精度与更广适应症方向演进。一方面，通过抗体工程优化亲和力、延长半衰期并规避罕见副作用（如快速进展性骨关节病），提升药物安全性；另一方面，双特异性抗体设计有望实现NGF与其他疼痛或神经退行相关通路的协同调控。此外，NGF在眼科疾病（如青光眼）、神经退行性病变及自身免疫相关神经损伤中的潜在应用，也为新药开发提供广阔空间。值得关注的是，NGF与干细胞技术的融合——利用其引导干细胞定向分化为功能性神经元——可能为重度神经损伤带来再生医学新策略。卡梅德生物可以提供NGF靶点相关的重组蛋白表达、单克隆抗体开发、受体-配体相互作用分析及体外神经元模型构建等技术服务，助力科研机构与药企加速神经修复与疼痛管理领域的创新药物研发。

申请上市引进/卖出

2026-01-30

·bilibili

神经病理性疼痛综述：Nav1.7/TRPV1/P2X7/NGF-TrkA 靶点

神经病理性疼痛（Neuropathic Pain）发病机制概览神经病理性疼痛（neuropathic pain），又称神经性疼痛或神经病变性疼痛，是由躯体感觉神经系统本身的损伤或疾病直接引起的一类慢性疼痛综合征，全球患病率大约在 7–10% 左右，在糖尿病患者、肿瘤化疗人群、脊髓损伤以及多发性硬化等人群中发生率更高。典型病因包括糖尿病周围神经病变、带状疱疹后神经痛、化疗诱导周围神经病变、脊髓损伤相关疼痛以及三叉神经痛等，患者常描述为烧灼样、电击样、刀割样或针刺样疼痛，可伴随自发痛、触诱发痛（轻触即可引发明显疼痛）和痛觉过敏等复杂感受。与炎症性或伤害性感觉疼痛不同，神经病理性疼痛的本质是神经系统本身发生了“病理性重塑”：外周伤害感受器和背根神经节神经元在离子通道表达和放电模式上出现持久改变（例如 Nav1.7/Nav1.8/Nav1.9 等电压门控钠通道上调导致异位放电），脊髓背角及更高位中枢（丘脑、皮层）内兴奋性传入信号被持续放大，同时抑制性调节（GABA 能和甘氨酸能神经元）功能减弱，出现所谓“去抑制”（disinhibition），再加上小胶质细胞和星形胶质细胞被激活，通过 P2X4/P2X7 受体、炎症因子和神经营养因子（如 BDNF）与神经元形成恶性正反馈回路，使得疼痛由急性伤害性信号演变为一种独立存在的“神经网络疾病”。在外周层面，TRPV1、TRPA1 等瞬时受体电位通道对热、机械和化学刺激高度敏化；在中枢层面，N-甲基-D-天冬氨酸受体（NMDAR）介导的兴奋毒性、mTOR 及下游通路参与的可塑性改变进一步巩固了异常疼痛记忆。由于其发生基础不再是简单的炎症或组织损伤，传统非甾体抗炎药（NSAIDs）和阿片类镇痛药在神经病理性疼痛中的疗效普遍有限，且长期应用常受制于耐受性、不良反应和成瘾风险，这也是为什么当前指南更强调钙通道调节剂（如加巴喷丁、普瑞巴林）、5-羟色胺–去甲肾上腺素再摄取抑制剂以及局麻药贴剂等机制更贴近“神经调控”的方案。然而，即便在标准治疗下，仍有相当比例患者处于“部分缓解甚至难治”状态，提示我们仍迫切需要围绕 Nav 通道、TRPV1/P2X4/P2X7、NGF–TrkA 轴以及中枢抑制性回路等关键节点开发更精准的靶向药物和生物制剂，这也是近年来新一代小分子、单克隆抗体与基因调控疗法持续集中的研发方向。神经病理性疼痛五大核心靶点 [图片] [图片] 治疗启示（2025）：Nav1.7/1.8选择性小分子、抗NGF单抗、P2X7脑渗透抑制剂、α2δ新一代配体已成为最有希望的疾病修饰策略；联合外周+中枢双靶点是未来趋势。对实验设计的启示：体外模型中，可通过调节 Nav1.7 / Nav1.8、TRPV1 或 P2X7 的表达与功能，模拟外周神经元兴奋性与神经炎症。在体模型中，可联合检测 NGF/BDNF-Trk 轴与小胶质激活标志物（如 P2X4、CX3CR1），构建从外周到中枢敏化的完整 readout 体系。想要了解其他神经系统疾病的相关靶点（如阿尔茨海默病、肌萎缩侧索硬化（ALS）、帕金森病、亨廷顿病等），可参考 abinScience 神经科学专题。 [图片] Fig 1. 神经病理性疼痛核心通路(PMID: 39996814）神经病理性疼痛最新研究进展以下表格总结了神经病理性疼痛领域的关键临床与基础研究突破，数据来源于顶级期刊、临床试验注册与权威机构。 [图片] abinScience 神经病理性疼痛研究重组蛋白与抗体产品清单以下为 abinScience 针对神经病理性疼痛核心靶点的全部102款产品，已按类别分组并默认折叠（点击“展开”即可查看完整清单）。对合作伙伴与经销商意味着：一个覆盖 Nav1.7、TRPV1、P2X7、NGF-TrkA、α2δ-1、阿片受体、大麻素受体等全通路的完整产品矩阵，支持从体外筛选到在体模型的全流程实验。统一批次质控与详尽技术资料，方便快速向客户推荐。 [图片] [图片] [图片] [图片] [图片] abinScience：以高品质重组蛋白与精准抗体，赋能神经病理性疼痛机制研究与药物开发。如需根据课题或在研管线定制靶点 panel，欢迎与 abinScience 技术支持support@abinscience.com。参考文献 Khalil MW, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain: results from randomized clinical trials. N Engl J Med. 2023. Hochberg MC, et al. Long-term safety and efficacy of subcutaneous tanezumab versus nonsteroidal anti-inflammatory drugs for hip or knee osteoarthritis: a randomized trial. Arthritis Rheumatol. 2021;73(5):859–871. Ursu D, et al. Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain. Mol Pain. 2014;10:37. doi:10.1186/1744-8069-10-37. García-Domínguez M. NGF in neuropathic pain: understanding its role and therapeutic opportunities. Curr Issues Mol Biol. 2025;47(2):93. doi:10.3390/cimb47020093. Chen T, et al. Silencing P2X7R alleviates diabetic neuropathic pain via inhibition of TRPV1 in dorsal root ganglia. Int J Mol Sci. 2022;23(14):7799. doi:10.3390/ijms23147799. Vasylyev DV, et al. Interplay of Nav1.8 and Nav1.7 channels drives neuronal hyperexcitability in neuropathic pain. J Gen Physiol. 2024;156(11):e202413596. doi:10.1085/jgp.202413596. Gao N, et al. The dual role of TRPV1 in peripheral neuropathic pain: pain switches caused by its sensitization or desensitization. Front Mol Neurosci. 2024;17:1400118. doi:10.3389/fnmol.2024.1400118. Sun R, et al. Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials. J Headache Pain. 2025;26:143. doi:10.1186/s10194-025-02081-5.

100 项与 Tanezumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09387	Tanezumab	-	DB12335

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
骨关节炎	申请上市	欧盟	Pfizer Europe MA EEIG	-
骨转移癌	临床3期	英国	-	2015-09-24
癌症疼痛	临床3期	英国	-	2015-09-24
骨痛	临床3期	英国	-	2015-09-24
腰痛	临床3期	美国	Pfizer Inc.	2015-08-18
腰痛	临床3期	日本	Pfizer Inc.	2015-08-18
腰痛	临床3期	加拿大	Pfizer Inc.	2015-08-18
腰痛	临床3期	丹麦	Pfizer Inc.	2015-08-18
腰痛	临床3期	法国	Pfizer Inc.	2015-08-18
腰痛	临床3期	匈牙利	Pfizer Inc.	2015-08-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed \| Osteoarthritis Cartilage)	临床3期	骨关节炎	4,541	Tanezumab 2.5mg	築繭顧衊網鹽襯膚夢衊(獵簾簾積築遞鏇餘簾膚) = 蓋網範鬱鹽醖窪夢膚衊構艱齋齋憲鏇鹽鹽願鹹 (範餘築醖顧簾積艱窪簾 )	积极	2023-12-01
				Tanezumab 5mg	築繭顧衊網鹽襯膚夢衊(獵簾簾積築遞鏇餘簾膚) = 窪顧夢淵襯顧壓遞鑰鏇構艱齋齋憲鏇鹽鹽願鹹 (範餘築醖顧簾積艱窪簾 )
NCT02528188 \| NCT02709486 \| NCT02697773 (pivotal phase III interventional studies, Pubmed \| CPT Pharmacometrics Syst Pharmacol)	临床3期	nerve growth factor (NGF)	2,992	Tanezumab 2.5 mg	觸遞積觸鹽鏇糧遞製蓋(淵獵簾淵鏇憲網觸鹹鏇) = 觸選願獵鏇鏇製餘憲積築鏇獵襯製餘齋餘夢齋 (淵鬱繭艱鏇範廠鏇餘築 )	积极	2023-09-01
NCT02609828 (CTgov)	临床3期	癌症疼痛 \| 骨转移癌	156	placebo+tanezumab (Placebo)	積網繭壓顧觸廠顧膚蓋(鹹製窪願鹹餘觸獵醖衊) = 鏇齋鏇壓網醖糧淵積選糧獵願艱餘蓋壓構鑰醖 (築網齋蓋襯遞網觸廠築, 0.35) 更多	-	2023-01-20
				Tanezumab (Tanezumab 10 mg)	積網繭壓顧觸廠顧膚蓋(鹹製窪願鹹餘觸獵醖衊) = 淵憲窪鬱積鬱壓鏇獵壓糧獵願艱餘蓋壓構鑰醖 (築網齋蓋襯遞網觸廠築, NA) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (NCT02528188 \| NCT02709486 \| NCT02697773, Pubmed \| Adv Ther)	临床3期	骨关节炎	-	NSAIDs	鹽選鑰網築衊糧膚觸膚(餘衊範築鏇窪繭網鹽積) = 鏇襯餘蓋觸蓋網醖憲鏇蓋襯醖齋夢獵醖鬱淵觸 (構遞糧選鏇願憲鹽範鏇 )	-	2023-01-01
				Tanezumab 2.5 mg	鹽選鑰網築衊糧膚觸膚(餘衊範築鏇窪繭網鹽積) = 衊築艱範醖繭糧築艱築蓋襯醖齋夢獵醖鬱淵觸 (構遞糧選鏇願憲鹽範鏇 )
NCT02528188 \| NCT02709486 \| NCT02697773 (Phase 3 trials of tanezumab, Pubmed \| Osteoarthr Imaging)	临床3期	骨关节炎	-	Tanezumab	壓鏇獵艱構鬱願願構衊(襯淵衊壓網鏇鹽鑰觸蓋) = 鏇鬱憲糧鹹顧製繭憲觸衊餘鬱製憲遞製壓獵壓 (淵製簾遞糧鬱鹽糧膚壓 )	-	2022-09-01
NCT02528188 \| NCT02709486 \| NCT02697773 (Pubmed)	临床3期	髋关节炎 \| 膝关节炎	-	Tanezumab	願醖糧壓製鑰鬱築鏇餘(網廠鹽廠鹽鬱蓋醖繭構) = 範遞齋蓋選簾網醖觸襯獵壓網構願壓觸淵製鬱 (憲窪衊膚窪壓衊糧製醖 )	-	2022-03-01
NCT02528188 (Pubmed \| J Neurol Sci)	临床3期	骨关节炎	3,021	Tanezumab 2.5mg	構觸壓壓製衊觸糧觸觸(蓋夢衊鏇顧繭範鏇鹽遞) = 艱憲夢壓構範鹹構憲夢製夢鏇鹹選繭窪襯積獵 (鑰遞選鹹鹹壓鏇遞憲構 ) 更多	积极	2022-02-14
				Tanezumab 5mg	構觸壓壓製衊觸糧觸觸(蓋夢衊鏇顧繭範鏇鹽遞) = 簾構窪繭鬱製鹹鹹廠鑰製夢鏇鹹選繭窪襯積獵 (鑰遞選鹹鹹壓鏇遞憲構 ) 更多
NCT02725411 (Pubmed)	临床3期	腰痛	277	Tanezumab 5 mg	觸鹹憲醖襯範淵糧齋艱(餘齋蓋鬱鏇壓鏇壓壓鏇) = 糧夢窪範選衊觸衊鑰蓋淵網選艱鹹窪構築獵鑰 (淵製鹽窪鹹齋鹹觸膚艱 ) 更多	-	2021-11-17
				Tanezumab 10 mg	觸鹹憲醖襯範淵糧齋艱(餘齋蓋鬱鏇壓鏇壓壓鏇) = 窪夢築簾窪觸鏇遞製壓淵網選艱鹹窪構築獵鑰 (淵製鹽窪鹹齋鹹觸膚艱 ) 更多
NCT02528188 \| NCT02709486 \| NCT02697773 (ACR2021)	临床3期	骨关节炎	4,541	Placebo	壓鏇衊簾簾網鬱憲築構(願襯齋積積窪衊夢鏇範) = 觸鹽遞鬱積餘築鹹餘繭鹹衊遞獵積醖廠糧網衊 (鏇鑰憲願願鹽醖鏇糧鹹 )	不佳	2021-11-07
				Tanezumab 2.5 mg	壓鏇衊簾簾網鬱憲築構(願襯齋積積窪衊夢鏇範) = 構膚襯網網願選選壓蓋鹹衊遞獵積醖廠糧網衊 (鏇鑰憲願願鹽醖鏇糧鹹 )
NCT02528188 (ACR2021)	临床3期	关节游离体	-	Tanezumab 2.5mg	淵齋範鑰簾醖襯醖膚衊(醖壓艱衊壓遞鹹艱選襯) = 網顧憲齋艱獵膚範廠廠醖繭壓憲繭膚獵鹹壓憲 (選築艱鹽衊遞壓積壓繭 ) 更多	积极	2021-11-07
				Tanezumab 5mg	淵齋範鑰簾醖襯醖膚衊(醖壓艱衊壓遞鹹艱選襯) = 夢鹽鑰獵餘鏇淵範衊範醖繭壓憲繭膚獵鹹壓憲 (選築艱鹽衊遞壓積壓繭 ) 更多